Resúmenes de Ponencias - Sociedad Española de Oncología Médica

29. Gatzemeier U, Groth G, Hirsh V, et al. Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with
non-small cell lung cáncer overexpressing HER2: results of a randomized phase II study. Proc ASCO. 2002;21 (Part 1
of 2). Abstract 1185.
30. Kim ES, Mauer AM, Fossella FV, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor
(EGFR) blocking antibody, in conbination with docetaxel in chemotherapy refractory/resistant patients with advanced
non-small cell lung cáncer (NSCLC). Proc ASCO. 2002;21 (Part 1 of 2). Abstract 1168.
31. MKris et al. A phase II trial of ZD1839 in advanced NSCLC patients who had failed platinum- and docetaxel based
regimens (IDEAL 2). Proc ASCO. 2002;21(Part 1 of 2). Abstract 1166.
32. M.Fukuoka. Final results from a phase II trial oz ZD1839 for patients with advanced NSCLC (IDEAL 1). Proc ASCO.
2002;21 (Part 1 of 2). Abstract 1188.
33. Rosell R, et al: Molecular markers and targeted therapy with novel agents: prospects in the treatment o NSCLC. Lung
cáncer 2003.
122
Congreso
IXSEOM